|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Seven of the 9 indeterminate and suspicious cases with the BRAF V600E mutation had surgical follow-up, and they were all confirmed to be PTC.
|
30620446 |
2019 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We analyzed mutations of BRAF (V600E) and TERT promoter (C228T, C250T) in tumor DNA from 141 patients (75 with classical variant PTC, CVPTC; 66 with follicular variant PTC, FVPTC) recruited through a multi-center study.
|
31454788 |
2019 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Evaluation of BRAF V600E mutation status combined with cytomorphological features for diagnosis of PTC in cytologically indeterminate thyroid nodules can significantly improve diagnostic accuracy and reduce the number of diagnostic operations (calculator available at www.ptc-calc.we2host.lt).
|
29566402 |
2019 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E and Retinoic Acid in Radioiodine-Refractory Papillary Thyroid Cancer.
|
30396219 |
2019 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We further discuss a case with a single BRAF V600E cytological mutant lacking a postoperative PTC diagnosis and discuss the limitations of BRAF V600E detection using puncture elution fluid.
|
31529211 |
2019 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In the Cancer Genome Atlas (TCGA) PTC cohort, higher ENS-653 expression was correlated with more frequent BRAF (V600E) mutation and poorer disease-free survival.
|
30940124 |
2019 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Detection of BRAF V600E mutation in fine-needle aspiration fluid of papillary thyroid carcinoma by droplet digital PCR.
|
30682328 |
2019 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
TERT or NRAS mutation was likely to coexist with BRAF V600E mutation in PTC.
|
31300059 |
2019 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The most common genetic alteration identified in papillary thyroid cancer (PTC) encodes a valine to glutamic acid change at position 600 (V600E) in the BRAF proto-oncoprotein.
|
30988823 |
2019 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We conclude that coexisting BRAF V600E and TERT mutations in patients with PTC are associated with poor initial prognostic factors and clinical course and may be useful for predicting a worse response to therapy, recurrence, and poorer outcome than in patients without the above mutations.
|
31305897 |
2019 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The immunocytochemical expression of VE-1 (BRAF V600E-related) antibody identifies the aggressive variants of papillary thyroid carcinoma on liquid-based cytology.
|
30875124 |
2019 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
PTC with BRAF V600E mutation showed higher expression of ATX, LPA1, LPA2, and LPA3 than PTC without BRAF V600E mutation (p < 0.001).
|
31455351 |
2019 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF V600E mutation was identified in 15/83 of PTCs and significantly correlated with higher age of patients and classical variant of PTC.
|
31085772 |
2019 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E mutations occur in approximately 40% of all patients with papillary thyroid cancer (PTC) and are associated with a worse prognosis in population studies.
|
31085763 |
2019 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E mutation papillary thyroid cancer (PTC) is more aggressive with a higher risk of lymph node involvement and a poorer prognosis.
|
30688735 |
2019 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
38.2% of human PTCs displayed high expression of AXL that positively correlated with RAI-refractoriness and disease persistence or recurrence, especially when combined with v-raf murine sarcoma viral oncogene homolog B(BRAF) V600E mutation.
|
31181609 |
2019 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E mutation in papillary thyroid cancer is correlated with adverse clinicopathological features but not with iodine exposure.
|
31135058 |
2019 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Associations of the BRAF V600E Mutation and PAQR3 Protein Expression with Papillary Thyroid Carcinoma Clinicopathological Features.
|
31758408 |
2019 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The Association of BRAF V600E Mutation With Tissue Inhibitor of Metalloproteinase-3 Expression and Clinicopathological Features in Papillary Thyroid Cancer.
|
29868127 |
2018 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
<b>Purpose:</b> Sixty percent of papillary thyroid cancers (PTC) have an oncogenic (V600E) BRAF mutation.
|
30065097 |
2018 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Immunohistochemical detection of the mutated BRAF V600E protein in PTC may facilitate mutational analysis in the clinical setting.
|
29254799 |
2018 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
IHC is a suitable method to screen BRAF V600E mutation in FFPE samples of CRCs and PTCs.
|
30009773 |
2018 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The mRNA and protein levels of MMP-9 had no association with BRAF V600E mutation in Iranian PTC patients.
|
30509240 |
2018 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The positive correlation observed between expression of BRAF V600E and PD-L1/PD-1 suggests that immunotherapies targeting PD-L1/PD-1 might be effective for PTC patients with the BRAF V600E mutation, which are refractory to radioiodine therapy.
|
29651624 |
2018 |
|
Papillary thyroid carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In this study, we used the KTC1 cell line as a model for human advanced papillary thyroid cancer (PTC) because the cells harbor the heterozygous BRAF (V600E) mutation together with the C250T TERT promoter mutation.
|
30265861 |
2018 |